作者: Mandeep R. Mehra , Patricia A. Uber , Walter E. Uber , Myung H. Park , Robert L. Scott
DOI: 10.1097/00001573-200203000-00002
关键词:
摘要: Endomyocardial biopsy has stood the test of time as a surveillance technique; however, expense, resources required, invasive nature, and low but definite risks have motivated investigators to pursue less techniques. The search for noninvasive techniques cardiac rejection centered on measurements function, intragraft electrical events, peripheral proteomic markers graft micronecrosis, immune activation, nonimmune accompaniments rejection. Although several investigations allude reasonable negative predictive value such monitoring, specificity these remains poor. Until well-constructed studies not only define values also appropriately evaluate clinical safety any approach, endomyocardial will remain gold standard.